Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes

American Journal of Medicine

Volumn 124, Issue 3, 2011, Pages 199-205

  Harman, S Mitchell ^a   Vittinghoff, Eric ^b   Brinton, Eliot A ^c   Budoff, Matthew J ^d   Cedars, Marcelle I ^b   Lobo, Rogerio A ^e   Merriam, George R ^f   Miller, Virginia M ^g   Naftolin, Frederick ^h   Pal, Lubna ⁱ   Santoro, Nanette ^j   Taylor, Hugh S ⁱ   Black, Dennis M ^b  

^a Kronos Longevity Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e Howard Hughes Medical Institute   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Cardiovascular disease; Estrogen; Hormones; Menopause; Women's health

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; PLACEBO; PROGESTERONE;

BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; CORONARY RISK; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MENOPAUSE; POSTMENOPAUSE; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SURVIVAL RATE; WOMEN'S HEALTH;

BREAST NEOPLASMS; CARDIOVASCULAR SYSTEM; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS; WOMEN'S HEALTH;

EID: 79952471772     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.09.021     Document Type: Review

References (81)

1. D. Lloyd-Jones, R.J. Adams, and T.M. Brown Heart disease and stroke statistics2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
2. T.L. Bush, L.D. Cowan, and E. Barrett-Connor Estrogen use and all-cause mortality Preliminary results from the Lipid Research Clinics Program Follow-Up Study JAMA 249 1983 903 906 (Pubitemid 13143290)
3. T.L. Bush, E. Barrett-Connor, and L.D. Cowan Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study Circulation 75 1987 1102 1109 (Pubitemid 17081015)
4. P.H. Wolf, J.H. Madans, F.F. Finucane, M. Higgins, and J.C. Kleinman Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort Am J Obstet Gynecol 164 1991 489 494
5. B.E. Henderson, A. Paganini-Hill, and R.K. Ross Decreased mortality in users of estrogen replacement therapy Arch Intern Med 151 1991 75 78
6. M.J. Stampfer, G.A. Colditz, and W.C. Willett Postmenopausal estrogen therapy and cardiovascular disease Ten-year follow-up from the Nurses' Health Study N Engl J Med 325 1991 756 762
7. B. Ettinger, G.D. Friedman, T. Bush, and C.P.J. Quesenberry Reduced mortality associated with long-term postmenopausal estrogen therapy Obstet Gynecol 87 1996 6 12 (Pubitemid 26015941)
8. F. Grodstein, M.J. Stampfer, and G.A. Colditz Postmenopausal hormone therapy and mortality N Engl J Med 336 1997 1769 1775
9. F. Grodstein, J.E. Manson, G.A. Colditz, W.C. Willett, F.E. Speizer, and M.J. Stampfer A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease Ann Intern Med 133 2000 933 941 (Pubitemid 32003509)
10. B. Ettinger, D.M. Black, and B.H. Mitlak Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 1999 637 645 (Pubitemid 29384151)
11. K.M. Randell, R.J. Honkanen, H. Kroger, and S. Saarikoski Does hormone-replacement therapy prevent fractures in early postmenopausal women? J Bone Miner Res 17 2002 528 533 (Pubitemid 34171768)
12. J.A. Cauley, J. Robbins, and Z. Chen Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial JAMA 290 2003 1729 1738 (Pubitemid 37430623)
13. A.R. Folsom, P.J. Mink, T.A. Sellers, C.P. Hong, W. Zheng, and J.D. Potter Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women Am J Public Health 85 1995 1128 1132
14. The Writing Group for the Women's Health Initiative Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
15. L. Bergkvist, H.-O. Adami, I. Persson, R. Hoover, and C. Schairer The risk of breast cancer after estrogen and estrogen-progestin replacement N Engl J Med 321 1989 293 297 (Pubitemid 19193804)
16. C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk JAMA 283 2000 485 491 (Pubitemid 30062864)
17. G.A. Colditz, S.E. Hankinson, and D.J. Hunter The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N Engl J Med 332 1995 1589 1593
18. N.F. Col, M.H. Eckman, and R.H. Karas Patient-specific decisions about hormone replacement therapy in postmenopausal women JAMA 277 1997 1140 1147 (Pubitemid 27157632)
19. G.L. Anderson, M. Limacher, and A.R. Assaf Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial JAMA 291 2004 1701 1712 (Pubitemid 38489892)
20. J.E. Manson, J. Hsia, and K.C. Johnson Estrogen plus progestin and the risk of coronary heart Disease N Engl J Med 349 2003 523 534 (Pubitemid 36951364)
21. J. Hsia, M.H. Criqui, and R.J. Rodabough Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative Circulation 109 2004 620 626 (Pubitemid 38198869)
22. F. Grodstein, T.B. Clarkson, and J.E. Manson Understanding the divergent data on postmenopausal hormone therapy N Engl J Med 348 2003 645 650 (Pubitemid 36204960)
23. A. Lemay The relevance of the women's health initiative results on combined hormone replacement therapy in clinical practice J Obstet Gynaecol Can 24 2002 711 715
24. M.E. Mendelsohn, and R.H. Karas Molecular and cellular basis of cardiovascular gender differences Science 308 2005 1583 1587 (Pubitemid 40807497)
25. P. Raggi, T.Q. Callister, and B. Cooil Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography Circulation 101 2000 850 855 (Pubitemid 30117879)
26. F. Naftolin, H.S. Taylor, and R. Karas The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition Fertil Steril 81 2004 1498 1501 (Pubitemid 38748989)
27. E.A. Brinton, H.N. Hodis, G.R. Merriam, S.M. Harman, and F. Naftolin Can menopausal hormone therapy prevent coronary heart disease? Trends Endocrinol Metab 19 2008 206 212 (Pubitemid 351997464)
28. S.M. Harman, and E.A. Brinton Biphasic effects of hormone treatment on risk of cardiovascular disease: resolving the paradox in postmenopausal women Menopausal Med 17 2009 S5 S8
29. M.R. Adams, T.C. Register, D.L. Golden, J.D. Wagner, and J.K. Williams Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis Arterioscler Thromb Vasc Biol 17 1997 217 221 (Pubitemid 27057346)
30. T.B. Clarkson, M.S. Anthony, and C.P. Jerome Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys J Clin Endocrinol Metab 83 1998 721 726 (Pubitemid 28496435)
31. T.B. Clarkson, M.S. Anthony, and T.M. Morgan Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens J Clin Endocrinol Metab 86 2001 41 47 (Pubitemid 32109773)
32. J.K. Williams, M.S. Anthony, and E.K. Honore Regression of atherosclerosis in female monkeys Arterioscler Thromb Vasc Biol 15 1995 827 836
33. S. Hulley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613 (Pubitemid 28502636)
34. R.P. Byington, C.D. Furberg, and D.M. Herrington Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy Arterioscler Thromb Vasc Biol 22 2002 1692 1697
35. D.M. Herrington, D.M. Reboussin, and K.B. Brosnihan Effects of estrogen replacement on the progression of coronary-artery atherosclerosis N Engl J Med 343 2000 522 529 (Pubitemid 30650747)
36. F. Grodstein, J.E. Manson, and M.J. Stampfer Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation J Womens Health (Larchmt) 15 2006 35 44 (Pubitemid 43192860)
37. J. Hsia, R.D. Langer, and J.E. Manson Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative Arch Intern Med 166 2006 357 365 (Pubitemid 43244325)
38. J.E. Rossouw, R.L. Prentice, and J.E. Manson Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause JAMA 297 2007 1465 1477 (Pubitemid 46556472)
39. J.E. Manson, M.A. Allison, and J.E. Rossouw Estrogen therapy and coronary-artery calcification N Engl J Med 356 2007 2591 2602 (Pubitemid 46961004)
40. S.R. Salpeter, J. Cheng, L. Thabane, N.S. Buckley, and E.E. Salpeter Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women Am J Med 122 2009 1016 1022 e1
41. S.R. Salpeter, N.S. Buckley, H. Liu, and E.E. Salpeter The cost-effectiveness of hormone therapy in younger and older postmenopausal women Am J Med 122 2009 42 52 e2
42. R.L. Prentice, J.E. Manson, and R.D. Langer Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause Am J Epidemiol 170 2009 12 23
43. R.J. Santen, D.C. Allred, and S.P. Ardoin Postmenopausal hormone therapy: an Endocrine Society Scientific Statement J Clin Endocrinol Metab 95 7 Suppl 1 2010 s1 s66
44. V.M. Miller, D.M. Black, and E.A. Brinton Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) J Cardiovasc Translat Res 2 2009 228 239
45. USFDA: PREMARIN® (conjugated estrogens tablets, USP). 2010: Wyeth Pharmaceuticals, 2002 http://www.wyeth.com/products/prescription?product=/wyeth- html/home/products/prescription/ PREMARIN%C2%AE%20%28conjugated%20estrogens%20tablets,%20USP%29/ PREMARIN%C2%AE%20%28conjugated%20estrogens%20tablets,%20USP%29-overview.html Accessed April 8, 2010
46. F. Grodstein, J.E. Manson, and M.J. Stampfer Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study A prospective, observational study Ann Intern Med 135 2001 1 8 (Pubitemid 32619277)
47. C.E. Chilvers, R.C. Knibb, S.J. Armstrong, K.L. Woods, and R.F. Logan Post menopausal hormone replacement therapy and risk of acute myocardial infarctiona case control study of women in the East Midlands, UK Eur Heart J 24 2003 2197 2205 (Pubitemid 37522672)
48. S. Toh, S. Hernandez-Diaz, R. Logan, J.E. Rossouw, and M.A. Hernan Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial Ann Intern Med 152 2010 211 217
49. E.L. Frome The analysis of rates using Poisson regression models Biometrics 39 1983 665 674
50. M.A. Hernan, A. Alonso, and R. Logan Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease Epidemiology 19 2008 766 779
51. C.N. Bairey Merz, B.D. Johnson, and S.L. Berga Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) J Womens Health (Larchmt) 18 2009 1315 1322
52. Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial JAMA 273 1995 199 208
53. G.M. Darling, J.A. Johns, P.I. McCloud, and S.R. Davis Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women N Engl J Med 337 1997 595 601 (Pubitemid 27360759)
54. D.M. Herrington, B.L. Werbel, W.A. Riley, B.E. Pusser, and T.M. Morgan Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease J Am Coll Cardiol 33 1999 2030 2037
55. C. Spencer, D. Crook, D. Ross, A. Cooper, M. Whitehead, and J. Stevenson A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels Br J Obstet Gynaecol 106 1999 948 953 (Pubitemid 29415626)
56. L.G. Futterman, and L. Lemberg Lp(a) lipoproteinan independent risk factor for coronary heart disease after menopause Am J Crit Care 10 2001 63 67 (Pubitemid 33605291)
57. A. Wakatsuki, Y. Okatani, N. Ikenoue, and T. Fukaya Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen Circulation 104 2001 1773 1778 (Pubitemid 32963341)
58. S. Stork, C. von Schacky, and P. Angerer The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial Atherosclerosis 165 2002 301 307 (Pubitemid 35333356)
59. B. Guzic-Salobir, I. Keber, I. Seljeflot, H. Arnesen, and L. Vrabic Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women J Intern Med 250 2001 508 515 (Pubitemid 34008761)
60. I. Seljeflot, H. Arnesen, A.E. Hofstad, and I. Os Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease Thromb Haemost 83 2000 944 948 (Pubitemid 30411698)
61. J.A. McCubbin, S.G. Helfer, F.S. Switzer 3rd, and T.M. Price Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease Am Heart J 143 2002 711 717 (Pubitemid 34454706)
62. P. Angerer, S. Stork, and C. von Schacky Influence of 17beta-oestradiol on blood pressure of postmenopausal women at high vascular risk J Hypertens 19 2001 2135 2142 (Pubitemid 33135233)
63. A. Scuteri, A.J. Bos, L.J. Brant, L. Talbot, E.G. Lakatta, and J.L. Fleg Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women Ann Intern Med 135 2001 229 238 (Pubitemid 32799336)
64. A. Telci, U. Cakatay, S.E. Akhan, M.E. Bilgin, A. Turfanda, and A. Sivas Postmenopausal hormone replacement therapy use decreases oxidative protein damage Gynecol Obstet Invest 54 2002 88 93 (Pubitemid 36164638)
65. C.H. Yen, C.C. Hsieh, S.Y. Chou, and Y.T. Lau 17Beta-estradiol inhibits oxidized low density lipoprotein-induced generation of reactive oxygen species in endothelial cells Life Sci 70 2001 403 413 (Pubitemid 34017535)
66. B.R. Bhavnani, A. Cecutti, A. Gerulath, A.C. Woolever, and M. Berco Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women Menopause 8 2001 408 419 (Pubitemid 33111576)
67. E. Arteaga, A. Rojas, P. Villaseca, and M. Bianchi The effect of 17beta-estradiol and alpha-tocopherol on the oxidation of LDL cholesterol from postmenopausal women and the minor effect of gamma-tocopherol and melatonin Menopause 7 2000 112 116 (Pubitemid 30151398)
68. C. Hermenegildo, M.C. Garcia-Martinez, J.J. Tarin, and A. Cano Estradiol reduces F2alpha-isoprostane production in cultured human endothelial cells Am J Physiol Heart Circ Physiol 283 2002 H2644 H2649
69. M.D. Luyer, S. Khosla, W.G. Owen, and V.M. Miller Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women J Clin Endocrinol Metab 86 2001 3629 3634 (Pubitemid 32755953)
70. H.E. Brussaard, J.A. Leuven, H.M. Krans, and C. Kluft The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus Vascul Pharmacol 39 2002 141 147 (Pubitemid 36398239)
71. Y. Zhang, B.V. Howard, and L.D. Cowan Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic American Indian women: The Strong Heart Study J Womens Health (Larchmt) 13 2004 155 163 (Pubitemid 38444315)
72. S. Vehkavaara, A. Silveira, and T. Hakala-Ala-Pietila Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women Thromb Haemost 85 2001 619 625 (Pubitemid 32293696)
73. P. Collins, M. Flather, B. Lees, R. Mister, A.J. Proudler, and J.C. Stevenson Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study Eur Heart J 27 2006 2046 2053 (Pubitemid 44412809)
74. E. Hoibraaten, E. Qvigstad, T.O. Andersen, M.C. Mowinckel, and P.M. Sandset The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolismresults from a randomized, double-blind, clinical trial Thromb Haemost 85 2001 775 781 (Pubitemid 32421807)
75. P.Y. Scarabin, E. Oger, and G. Plu-Bureau Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432 (Pubitemid 36999704)
76. M. Canonico, E. Oger, and G. Plu-Bureau Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens, The ESTHER study Circulation 115 2007 840 845 (Pubitemid 46294724)
77. P. Hu, G.A. Greendale, and S.L. Palla The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: the postmenopausal estrogen progestin intervention (PEPI) trial Atherosclerosis 185 2006 347 352
78. K.C. Lewandowski, J. Komorowski, and D.P. Mikhalidis Effects of hormone replacement therapy type & route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women J Clin Endocrinol Metab 91 2006 3123 3130 (Pubitemid 44271767)
79. T. Suzuki, and D.A. Sullivan Estrogen stimulation of proinflammatory cytokine and matrix metalloproteinase gene expression in human corneal epithelial cells Cornea 24 2005 1004 1009 (Pubitemid 41688540)
80. C.S. Wingrove, E. Garr, I.F. Godsland, and J.C. Stevenson 17beta-oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells Biochim Biophys Acta 1406 1998 169 174 (Pubitemid 28193070)
81. M.A. Hamburg, and F.S. Collins The path to personalized medicine N Engl J Med 363 2010 301 304 No abstract available. Erratum in: N Engl J Med. 2010;363:1092